Nuage Therapeutics
PrivateLast Round
Grant
Dec 2, 2025
Total Funding Raised
$18.08M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Nuage Therapeutics operates in Healthcare & Life Sciences and is based in Barcelona. Its latest recorded funding round was a Grant round in December 2025.
Nuage Therapeutics is a biotechnology company that develops drugs designed to target intrinsically disordered proteins for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuage Therapeutics Comparables
Compare Nuage Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Medusa Therapeutics Limited | 91% | |
| Topos Bio | 87% | |
| Transition Bio, Inc. | 85% |
For institutional investors. Book with your work email.
Nuage Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 2, 2025 | ||||
| Seed | May 26, 2025 | ||||
| Seed | Jun 20, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nuage Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Asabys Partners | Seed |
| Agencia Estatal de Investigación | Grant |
| Sofinnova Partners | Seed |
| Center for Technological Development and Innovation | Seed |
| BStartup Banco Sabadell | Seed |
| Innvierte | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 98% MoM, reaching 1.1K.
- Dec 2, 2025
$3.1M grant received from Agencia Estatal de Investigación.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardSep 1, 2026
Nuage receives the BioCentury Rising Star Award from BioCentury at Grand Rounds Europe in Sep '26 for its translational innovation and proprietary technology platform for intrinsically disordered proteins.
For institutional investors. Book with your work email.
Nuage Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nuage Therapeutics's valuation, stock price, and market status.
Is Nuage Therapeutics a public or private company?
Nuage Therapeutics is a private company.
What is the current stock price of Nuage Therapeutics?
Nuage Therapeutics is a private company, so its shares have no public market price. Caplight tracks Nuage Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nuage Therapeutics worth (valuation)?
Valuation information for Nuage Therapeutics is not publicly available.
Can I buy Nuage Therapeutics stock?
Nuage Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nuage Therapeutics's last funding round?
Nuage Therapeutics's most recent funding round was Grant on December 2, 2025.
Who are the main investors in Nuage Therapeutics?
Key investors in Nuage Therapeutics include Asabys Partners, Sofinnova Partners, Center for Technological Development and Innovation.
Will Nuage Therapeutics IPO soon?
No public IPO plans have been announced for Nuage Therapeutics.
How can I track Nuage Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Nuage Therapeutics's shares on secondary markets.